Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04121299
Other study ID # IRB-300004152
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date July 2021
Est. completion date June 2026

Study information

Verified date October 2021
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To test the hypothesis that sympatholytic antihypertensive antihypertensive therapy (αβ-blocker - carvedilol) will reduce out-of-clinic ambulatory BP to a greater extent by blocking sympathetic activity than non-sympatholytic antihypertensive medication (dihydropyridine calcium channel blocker - amlodipine) in individuals with masked hypertension.


Description:

A. Participants. Study participants with masked hypertension (MH) with controlled clinic BP (< 130/80 mmHg) and uncontrolled out-of-clinic awake ambulatory BP (ABP ≥ 130/80 mmHg) untreated with antihypertensive medications will be recruited. B. Study design. This is a double-blinded, randomized, 2-period, 2-treatment crossover clinical trial comparing sympatholytic antihypertensive agent (αβ-blocker - carvedilol 40mg extended release once daily) with non-sympatholytic control agent (dihydropyridine calcium channel blocker - amlodipine 10mg once daily) in individuals with MH. All study participants will undergo out-of-clinic 24hr ABP with actigraphy monitoring for 24-hr, awake and asleep ABP; sympathetic activity assessment by BP and HR variability, 24-hour urinary catecholamines and metanephrines at baseline and after intervention. In order to avoid selection bias, patients will be randomized to their initial therapy. Patients and study personnel will be blinded to the treatment group in order to minimize information bias. An investigator without direct study involvement will be assigned the task of ensuring correct dispensing of the study medication, which will be prepared as matching capsules by the UAB Pharmacy - Investigational Drug Service. After 4 weeks of initial treatment, both treatment groups will undergo a 1-month washout where no study medication is given in order to prevent a carryover effect. The study medication will be taken in the morning between 6 and 9 am except for study visit days. A crossover design is chosen to minimize differences between study groups, as participants will act as their own controls. Electrolytes, kidney function and ECG will be monitored at each visit. Medication adherence will be determined at visit 2 (week 4) and visit 4 (week 12) by measuring 24-hr urinary specimens for medications and their metabolites by LC-MS/MS and by pill count and medication log. C. Outcomes. The primary outcome is the difference in percent change in out-of-clinic mean 24-hr ABP, awake ABP and asleep ABP with carvedilol compared to amlodipine. Secondary outcomes include change in out-of-clinic sympathetic activity by BP and HR variability; and 24-hour urinary catecholamines and metanephrines. D. Preliminary / anticipated results. We anticipate a greater reduction in out-of-clinic 24-hr, awake and asleep ABP due to blocking of sympathetic activity with carvedilol when compared to amlodipine use in individuals with MH. A statistically significant effect estimate will support our hypothesis that higher sympathetic activity contributes to MH, which can be managed by use of sympatholytic agents like carvedilol.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Study participants with masked hypertension i.e. controlled clinic blood pressure (BP) and uncontrolled out-of-clinic awake ambulatory BP will be enrolled. A. Inclusion criteria. - Adults (18-75 years of age) - Controlled clinic BP (< 130/80 mmHg) untreated with antihypertensive medications - Uncontrolled awake ambulatory BP (= 130/80 mmHg) untreated with antihypertensive medications B. Exclusion criteria. - Hypertensive (Clinic BP = 130/80 mmHg) - Hypotensive (Clinic BP < 90/70 mmHg) - Bradycardic (Heart rate < 60 beats/minute) - Heart block - Use of an antihypertensive medication within the last 3 months - Use of an steroid containing medications within the last 3 months - Body mass index = 30 Kg/m2 - Chronic kidney disease (Estimated GFR < 60 mL/min/1.73m2) - Primary aldosteronism - Renal artery stenosis - Pheochromocytoma - Diabetes mellitus - Pregnant women - Breast feeding women - Dementia and/or cognitive impairment prohibiting consent - History of stroke within the past 6 months - History of unstable angina within the past 6 months - History of myocardial infarction within the past 6 months - Allergy or intolerance to ß-blockers - Allergy or intolerance to calcium channel blockers

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Carvedilol
Carvedilol 40mg Extended Release Once Daily
Amlodipine
Amlodipine 10mg Once Daily

Locations

Country Name City State
United States Hypertension Research Clinic at UAB Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Out of clinic 24 hour ambulatory blood pressure Difference in percent change in out-of-clinic mean 24-hr ambulatory BP in mmHg with carvedilol compared to amlodipine. 4 weeks
Primary Out of clinic awake blood pressure Difference in percent change in out-of-clinic mean awake ambulatory BP in mmHg with carvedilol compared to amlodipine. 4 weeks
Primary Out of clinic asleep blood pressure Difference in percent change in out-of-clinic mean asleep ambulatory BP in mmHg with carvedilol compared to amlodipine. 4 weeks
Secondary Out of clinic blood pressure variability Change in out-of-clinic sympathetic activity by BP variability in mmHg with carvedilol compared to amlodipine. 4 weeks
Secondary Out of clinic heart rate variability Change in out-of-clinic sympathetic activity by HR variability in beats/minute with carvedilol compared to amlodipine. 4 weeks
Secondary Out of clinic 24-hour urinary catecholamines Change in out-of-clinic sympathetic activity by 24-hour urinary catecholamines levels with carvedilol compared to amlodipine. 4 weeks
Secondary Out of clinic 24-hour urinary metanephrines Change in out-of-clinic sympathetic activity by 24-hour urinary metanephrines levels with carvedilol compared to amlodipine. 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT02804074 - MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement N/A
Active, not recruiting NCT02503943 - Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes Phase 4
Recruiting NCT02156024 - The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension Phase 4
Completed NCT02142881 - Treatment of Masked Hypertension Phase 3
Active, not recruiting NCT04200716 - Arterial Function After Two Different Physical Exercise Intensities in Prehypertension N/A
Not yet recruiting NCT05409898 - Screening for Masked Hypertension With Smart Wearable Devices (SMART)
Active, not recruiting NCT02893358 - Antihypertensive Treatment in Masked Hypertension for Target Organ Protection Phase 4
Recruiting NCT02663336 - Prevalence of Masked Hypertension in Nephrological Patients
Completed NCT04251975 - Masked Hypertensive Patients With Obstructive Sleep Apnea N/A